Novo Nordisk spokesperson: The Cagrisema trial allowed for dose reduction; even though only 57% of Cagrisema patients reached the highest dose, statistically significant results were achieved.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.
Weekly Highlights